Observational studyBMC infectious diseases2026
Clinical management of Xpert
Observational study in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInterpreting trace results from the Xpert® MTB/RIF Ultra assay, a frontline diagnostic tool for tuberculosis, remains challenging, particularly in low-tuberculosis burden settings. This study aimed to provide practical recommendations for managing trace-positive patients in Lebanon based on clinical, radiological, and bacteriological data.
methodsA retrospective observational study was conducted at the National Tuberculosis Reference Laboratory in Lebanon, Laboratoire Rodolphe Mérieux, from January 2020 to December 2024. Samples referred by the Lebanese National Tuberculosis Program for both Xpert® MTB/RIF Ultra and mycobacterial culture were included. Non-conforming samples or those with invalid/error Xpert® MTB/RIF Ultra results were excluded. For patients with trace-positive results, correlations were assessed with microbiological parameters (microscopy and culture), clinical characteristics (symptoms, prior TB history and treatment initiation) and radiological findings. Diagnostic accuracy and case classification were assessed using a Composite Clinical Reference Standard (CRS) that excluded the index test to avoid incorporation bias.
resultsAmong 1,061 Ultra tests, 42 (4.0%) yielded trace-positive results. Patients with trace results had a mean age of 42 years (range: 0–75), and 59.5% were female. Two patients (4.8%) had a history of prior tuberculosis treatment, and one (2.4%) was HIV-positive. Most trace-positive results (33 cases; 78.6%) were derived from respiratory specimens. Culture confirmed Mycobacterium tuberculosis complex in 9 cases (21.4%). Using the CRS, 20 patients (47.6%) were classified as Definite TB (9 patients) or Probable TB (11 patients) and initiated first‑line therapy; 17 of them (85.0%) achieved favorable outcomes.
conclusionIn low‑burden settings like Lebanon, the interpretation of Xpert® MTB/RIF Ultra trace results is strengthened by applying a Composite Clinical Reference Standard that integrates clinical, radiological, and microbiological criteria. This approach supports more informed clinical classification, guides appropriate treatment decisions, and was associated with favorable outcomes in our cohort. These exploratory findings support the potential value of CRS‑based frameworks and warrant confirmation in prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.